Nickel (Ni), one of the most abundant transition metals in the earth's crust, is widely distributed in the environment. Natural sources of atmospheric Ni include dusts from volcanic emissions and the weathering of rocks and soils ([@r18]). Ni and its compounds have many industrial and commercial uses, and the progress of industrialization has led to increased emission of this environmental pollutant into our ecosystems. Ni is used in modern industry with other metals to form alloys to produce coins, jewelry, household and cooking utensils, batteries, orthopedic implants, and orthodontic appliances such as braces and dental appliances ([@r5]). Environmental exposure to Ni by the general population occurs primarily via oral intake, as a contaminant in drinking water or as either a constituent or contaminant of foods, including chocolate, nuts, and grains ([@r5]).

Occupational exposure to Ni occurs predominantly in the mining, refining, alloy production, electroplating, and welding industries ([@r10]; [@r13], [@r12]). Epidemiological studies of Ni compounds from occupationally exposed populations have reported that exposure to Ni compounds is associated with lung and nasal cancers and increased risks for acute respiratory syndromes, most clearly demonstrated in Ni refinery workers ([@r10]; [@r12]; [@r25]). In 1990, the International Agency for Research on Cancer (1990) classified Ni compounds as carcinogenic to both humans and experimental animals.

The eukaryotic genome is packaged into chromatin, the fundamental subunit of which is the nucleosome. Each nucleosome contains 146 bp DNA wrapped around an octamer of core histones. Two copies of each of histone, H2A, H2B, H3, and H4, form the histone core octamer.

Posttranslational modifications (i.e., acetylation, methylation, phosphorylation, ubiquitination) on the tails of the histone proteins play an important role in regulating chromatin biology ([@r30]; [@r33]). These specific histone modifications and their combinations are translated, through protein interactions, into distinct effects on nuclear processes, such as activating or inhibiting transcription ([@r16]). Acetylation of lysines on histone tails is associated with transcriptional activation ([@r1]). Methylation of histones H3K4 and H3K36 is associated with actively transcribed genes, whereas methylation of H3K9, H3K27, and H4K20 is associated with transcriptional repression. Furthermore, lysine residues on histone tails can be mono-, di-, or trimethylated, and the degree of methylation on H3K4, H3K9, H3K27, and H4K20 has considerable influence on transcriptional activation or repression ([@r11]; [@r26]; [@r28]; [@r32]). For example, H3K4 trimethylation and H3K9 acetylation are generally associated with transcriptional activation, whereas H3K9 dimethylation is associated with transcriptional repression ([@r11]).

Ni compounds were found to have weak mutagenic activity in our laboratory ([@r3]; [@r21]). In other laboratories, nickel subsulfide and green nickel oxide did not induce mutation to ouabain resistance in C3H/10T12 mouse embryo cells, nor did nickel subsulfide induce mutation to ouabain resistance or to 6-thioguanine resistance in cultured human diploid fibroblasts, although crystalline nickel monosulfide and green nickel oxide did induce amplification of the ect-2 protooncogene in C3H/10T1/2 mouse embryo cells ([@r2]; [@r9]; [@r22]). Therefore, Ni carcinogenesis likely proceeds through a combination of genetic (mutation and gene amplification) and epigenetic mechanisms ([@r3]; [@r9]; [@r17]; [@r19], [@r20]).

Previous studies have shown that *in vitro* exposure to Ni can perturb DNA methylation patterns as well as global and gene-specific levels of histone modifications. Ni-induced changes in histone modifications include loss of acetylation on histones H2A, H2B, H3, and H4and increases in histone H3K9me2 and H3K4me3, and ubiquitination of histones H2A and H2B ([@r7]; [@r17]; [@r20]; [@r34]). However, the studies examining the changes in global and gene-specific DNA methylation patterns and histone modifications induced by exposure to Ni compounds have only been conducted in tissue culture model systems.

The present study was conducted in a Chinese population to determine whether occupational exposure to the Ni dusts from refining sulfidic Ni ores is associated with alterations in global levels of H3K4 trimethylation (leading to H3K4me3), H3K9 acetylation (leading to H3K9ac), and H3K9 dimethylation (leading to H3K9me2) histone modifications in peripheral blood mononuclear cells (PBMCs) of subjects. Additionally, the inter- and intraindividual variance of global levels of H3K4me3, H3K9ac, and H3K9me2 histone modifications in PBMCs of subjects was evaluated to determine if measurements of global levels of histone modifications are stable over time.

Materials and Methods
=====================

*Study site and subject recruitment.* This study was conducted among workers of a Ni refinery in Jinchang, China, and local residents in Gansu, China. The human subject protocol for this study was approved by the institutional review boards of both the New York University School of Medicine and the Lanzhou University School of Public Health. Written informed consent was obtained from all participating subjects.

We recruited 120 healthy male subjects between 24 and 56 years of age for this study; subjects with diagnosed chronic diseases, including cancer, were excluded. For phase 1 of the study, 30 subjects who had high occupational exposure to Ni for at least 1 year at a Ni refinery in Jinchang, China, having worked in the flash smelting workshop where sulfidic Ni ores are processed, were recruited through questionnaire interview. Sixty referent subjects, who were maintenance or office workers, with no reported occupational exposure to Ni, were enrolled from residents in Gansu, China. The referents were frequency matched (2:1) by age and smoking habits with the 30 recruited occupationally exposed workers. For phase 2 of the study, 15 additional subjects with occupational exposure to Ni and 15 additional referent subjects were recruited, as in phase 1. The phase 1 study was conducted to determine whether exposure to Ni is associated with alterations in global levels of histone modification markers in the PBMCs of subjects. The phase 2 study was conducted to evaluate the inter- and intraindividual variability of global levels of histone modifications. Ni-exposed subjects are exposed to Ni ambient concentrations as high as 1 mg/m^3^. Referent subjects are exposed to Ni ambient concentrations of 204.8 ± 268.6 ng/m^3^.

*Sample collection and handling.* In the phase 1 study, a single blood and urine sample was collected. For phase 2, blood and urine samples were collected at three different time points, with a 1-week interval between collections. Blood samples (20 mL) were obtained by venipuncture by a local registered nurse. Blood was collected into two heparin-containing Vacutainer tubes, and all blood samples were temporarily kept at 4°C until transported to the local laboratory for isolation of PBMCs using a standardized Ficoll-Hypaque gradient procedure. Fifty microliters of urine was collected from each study subject. The isolated lymphocyte pellet and urine samples were stored frozen at --80°C and hand-carried frozen on dry ice to New York University.

*Histone extraction.* Histones were extracted from PBMCs as described previously ([@r7]) with a slight modification ([@r27]). Briefly, cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 1 mM Na~3~3VO~4~, 1 mM NaF) supplemented with a protease inhibitor mixture (Roche Applied Sciences, Indianapolis, IN, USA) for 10 min. The pellet was collected by centrifugation at 10,000 × *g* for 10 min. The pellet was washed once in 10 mM Tris-HCl and 37 mM EDTA (pH 7.4), and resuspended in 200 µL 0.4 N H~2~SO~4~. After overnight incubation on ice, the supernatant was collected by centrifugation at 14,000 × *g* for 15 min and mixed with 2 mL cold acetone and kept at −20°C overnight. The histones were collected by centrifugation at 14,000 × *g* for 15 min. After one wash with acetone, the histones were air dried and suspended in sterile deionized water. Total histone concentration in each sample was measured using the Bradford assay according to the manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA, USA).

*Measurement of global histone modification.* Histone modification measurements were determined using a sandwich enzyme-linked immunosorbent (ELISA) assay. Polystyrene 96-well microplates (Fisher Scientific, Pittsburg, PA, USA) were coated with 100 µL of histone H3 antibody (Abcam, Cambridge, MA, USA) at a concentration of 1:20,000 diluted in PBS and incubated overnight at 4°C. The plates were washed with PBST (1× PBS, 0.05% Tween-20) and blocked for 2 hr at room temperature with 5% milk in PBST. The plates were washed with PBST and the desired amount of standard recombinant proteins (for measurement of the standard curve for H3K9me2 or H3K4me3; Active Motif, Carlsbad, CA, USA) or calf histone proteins (for measurement of the standard curve for H3K9ac; Sigma, Saint Louis, MO, USA) were added to each well, followed by the addition of PBMC histones diluted in water. Plates were incubated at room temperature for 1.5 hr with agitation on an orbital shaker. After incubation, the wells were washed with PBST, and 100 µL diluted primary antibody \[histone H3 (Sigma), H3K9me2 (Abcam, Cambridge, MA, USA), H3K4me3 (Millipore, Billerica, MA, USA), or H3K9ac (Abcam)\] was added to each well separately and incubated at room temperature for 1 hr with agitation. The wells were then washed with PBST, and 100 µL diluted secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to each well and incubated at room temperature for 1 hr without agitation. Wells were washed with PBST and 100 µL of TMB (3,3´, 5,5˝-tetramethylbenzidine; Fisher Scientific) solution was added to each well and incubated at room temperature for 30 min in the dark. The reaction was stopped by adding 100 µL 2 M H~2~SO~4~ to each well. All analyses were performed in triplicate. The optical density was read at 450 nm using the SoftMax Pro software (version 5.2) and the SpectraMax 190 microplate reader (both from Molecular Devices, Sunnyvale, CA, USA). The relative percent histone modification was derived from standard curves specific to each histone modification. The respective within- and between-assay coefficients of variation for each modification were the following: H3K9me2, 3.9% and 6.6%; H3K9ac, 3.5% and 6.3%; and H3K4me3, 3.8% and 5.6%. Representative standard curves for H3, H3K4me3, H3K9ac, and H3K9me2 are provided in Supplemental Material \[[Figure 1](#f1){ref-type="fig"} (<http://dx.doi.org/10.1289/ehp.1104140>)\]. In phase 1, histone modifications for 23 Ni-exposed and 42 referent subjects were characterized. In phase 2, histone modifications for 15 Ni-exposed and 15 referent subjects were characterized. Measurements of global histone modifications were not measured for all subjects recruited into the study as proposed because of technical difficulties that occurred during the initial assay development.

![Association of urinary levels with global H3K4me3 (*y* = 0.02*x* + 0.1, *r* = 0.4, *p* = 0.0008) (*A*), H3K9ac (*y* = --0.08*x* + 1.8, *r* = 0.3, *p* = 0.0114) (*B*), and H3K9me2 (*y*= --0.003*x* + 0.2, *r* = 0.1, *p* = 0.4174) (*C*) from Ni-exposed and referent study subjects.](ehp.1104140.g001){#f1}

*Measurement of urinary Ni, cotinine, and creatinine.* Urinary Ni, used to index the individual personal exposure to Ni, was analyzed for all study subjects by inductively coupled plasma mass spectroscopy (Elan DRCII; PerkinElmer, Norwalk, CT USA) ([@r23]). Urinary cotinine, a major metabolite of nicotine and a valid biomarker of environmental tobacco smoke, was measured in each subject to confirm smoking status and control its potential confounding effects. Urinary cotinine measurements were measured using a Cotinine Direct ELISA kit (Immunalysis, Pomona, CA, USA) ([@r14]). Urinary creatinine was measured in order to adjust the Ni and cotinine levels in urine samples. Urinary creatinine measurements were determined using the creatinine incorporating dynamic stabilization technology assay kits (Fisher Scientific) according to the standard procedure.

*Statistical analysis.* Differences in age, self-reported smoking data (number of smokers, number of years smoking, and cigarettes per day smoked for smokers), urinary cotinine, urinary Ni, and global levels of histone modifications among groups were compared by two-sample Student's *t*-test. Differences in number of smokers and nonsmokers between exposure groups were compared by chi-square test. Linear regression analysis was used to evaluate the association of histone modification levels with urinary Ni levels. Multiple linear regression analysis was used to examine the association between urinary Ni and histone modification levels, while controlling for age and cigarette smoking as confounding factors. All *p*-values were two sided, with *p* \< 0.05 considered statistically significant. Statistical analyses were performed in S-Plus statistical analysis software (TIBCO Software Inc., Palo Alto, CA, USA).

Results
=======

The phase 1 study of 30 subjects with high occupational exposure to Ni and 60 referents was designed to determine whether exposure to Ni induces alterations in global levels of histone modifications in PBMCs of subjects. As shown in [Table 1](#t1){ref-type="table"}, no significant difference was found between Ni-exposed and referent subjects with respect to age, self-reported data on smoking habits, or urinary cotinine levels. Although a large percentage of subjects reported that they were smokers in both groups, the Ni concentrations in blood plasma and urine are quite similar among smokers and nonsmokers ([@r29]). Urinary Ni was elevated in Ni-exposed subjects (5.68 ± 1.88 µg/g), compared with referents (3.96 ± 1.40 µg/g; *p* = 0.0006). H3K4me3 was elevated in the PBMCs of Ni-exposed subjects (0.25% ± 0.11%) compared with referents (0.15% ± 0.04%; *p* = 0.0004). H3K9me2 was decreased in the PBMCs of Ni-exposed subjects (0.11% ± 0.05%) compared with referents (0.15% ± 0.04%; *p* = 0.0027). H3K9ac did not differ significantly between groups (1.28% ± 0.55% for Ni-exposed subjects, 1.50% ± 0.36% for referents; *p* = 0.0981).

###### 

Characteristics of the study subjects selected to study the alterations in histone modifications associated with occupational exposure to Ni (mean ± SD).

  Parameter                                                                                                                                                                                                                                                                                                     Referent subjects*a*   Ni-exposed subjects*a*   *p*-Value                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------ ----------- --------------------- -- --------
  Age (years)                                                                                                                                                                                                                                                                                                                          42.26 ± 6.19                         43.74 ± 4.12             0.2626
  Smoking (self-reported)                                                                                                                                                                                                                                                                                                                                                                            
  Smokers \[*n* (%)\]                                                                                                                                                                                                                                                                                                                  33 (79)                              19 (83)                  0.2601
  Smoking years                                                                                                                                                                                                                                                                                                                        17.03 ± 9.08                         18.32 ± 6.79             0.5734
  Cigarettes/day                                                                                                                                                                                                                                                                                                                       14.73 ± 9.58                         18.11 ± 8.52             0.2028
  Urinary cotinine (µg/g creatinine)                                                                                                                                                                                                                                                                                                   8401.53 ± 9440.94                    11517.86 ± 10049.98      0.2375
  Urinary Ni (µg/g creatinine)                                                                                                                                                                                                                                                                                                         3.96 ± 1.40                          5.68 ± 1.88              0.0006
  Median                                                                                                                                                                                                                                                                                                                               3.88                                 5.55                     
  Minimum                                                                                                                                                                                                                                                                                                                              1.19                                 2.49                     
  Maximum                                                                                                                                                                                                                                                                                                                              6.91                                 9.43                     
  10th percentile                                                                                                                                                                                                                                                                                                                      2.30                                 3.54                     
  25th percentile                                                                                                                                                                                                                                                                                                                      3.18                                 4.01                     
  75th percentile                                                                                                                                                                                                                                                                                                                      4.73                                 7.07                     
  90th percentile                                                                                                                                                                                                                                                                                                                      6.04                                 8.13                     
  Histone modifications (relative %)                                                                                                                                                                                                                                                                                                                                                                 
  H3K4me3                                                                                                                                                                                                                                                                                                                              0.15% ± 0.04                         0.25% ± 0.11             0.0004
  H3K9ac                                                                                                                                                                                                                                                                                                                               1.50% ± 0.36                         1.28% ± 0.55             0.0981
  H3K9me2                                                                                                                                                                                                                                                                                                                              0.15% ± 0.04                         0.11% ± 0.05             0.0027
  **a**Histone modifications for 42 referent subjects and 23 Ni-exposed subjects were characterized. Global histone modifications were not measured for all 60 referent subjects and 30 Ni-exposed subjects as proposed because of technical difficulties that occurred during the initial assay development.                                                                                        

Linear regression analysis was used, combining data from Ni-exposed and referent subjects, to determine whether levels of urinary Ni were associated with the extent of H3K4me3, H3K9ac, and H3K9me2 histone modifications. H3K4me3 was positively associated ([Figure 1A](#f1){ref-type="fig"}; *p* = 0.0008) and H3K9ac was negatively associated ([Figure 1B](#f1){ref-type="fig"}; *p* = 0.0114) with urinary Ni, whereas H3K9me2 did not correlate with urinary Ni ([Figure 1C](#f1){ref-type="fig"}; *p* = 0.4174).

Multiple regression analyses results indicated that age and cigarette smoke were not confounders for the association observed between urinary Ni and global histone modifications, with positive correlations between H3K4me3 and urinary Ni levels remaining after adjustment for age and self-reported smoking data ([Table 2](#t2){ref-type="table"}; *p* = 0.001) and for age and urinary cotinine levels ([Table 2](#t2){ref-type="table"}; *p* = 0.001). Also, a negative correlation was observed between urinary Ni and H3K9ac, after adjustment for age and self-reported smoking ([Table 3](#t3){ref-type="table"}; *p* = 0.01) and age and urinary cotinine levels ([Table 3](#t3){ref-type="table"}; *p* = 0.01). Correlations remained absent between H3K9me2 and urinary Ni levels when adjusted for age and self-reported smoking data ([Table 4](#t4){ref-type="table"}; *p* = 0.49) and for age and urinary cotinine levels ([Table 4](#t4){ref-type="table"}; *p* = 0.49).

###### 

Summary of multiple regression analyses of global H3K4me3 on urinary Ni levels (µg/g) with adjustment of potential confounders.

  Parameter                      Estimate ± SE   *p*-Value                            
  ------------------------------ --------------- --------------------------------- -- -------------
  Without adjustment                                                                  
  Intercept                                      0.99 ± 0.27                          5 × 10^--4^
  Urinary Ni                                     0.19 ± 0.05                          8 × 10^--4^
  Adjusted by age and smoking                                                         
  Intercept                                      1.12 ± 8.86                          0.90
  Urinary Ni                                     1.87 ± 0.55                          1 × 10^--3^
  Age                                            0.23 ± 0.18                          0.22
  Smoking (self-reported)                        --0.79 ± 2.55                        0.76
  Adjusted by age and cotinine                                                        
  Intercept                                      --3.30 ± 7.84                        0.68
  Urinary Ni                                     1.86 ± 0.54                          1 × 10^--3^
  Age                                            0.28 ± 0.17                          0.11
  Urinary cotinine                               1.64 × 10^--4^ ± 9.88 × 10^--5^      0.10
                                                                                      

###### 

Summary of multiple regression analyses of global H3K9ac on urinary Ni levels (µg/g) with adjustment of potential confounders.

  Parameter                      Estimate ± SE                     *p*-Value
  ------------------------------ --------------------------------- ----------------
  Without adjustment                                               
  Intercept                      1.77 ± 14.55                      \< 1 × 10^--4^
  Urinary Ni                     --7.73 ± 2.96                     0.01
  Adjusted by age and smoking                                      
  Intercept                      168.37 ± 48.22                    9 × 10^--4^
  Urinary Ni                     --7.61 ± 2.99                     0.01
  Age                            --0.07 ± 1.00                     0.94
  Smoking (self-reported)        14.77 ± 13.87                     0.29
  Adjusted by age and cotinine                                     
  Intercept                      175.78 ± 43.04                    1 × 10^--4^
  Urinary Ni                     --7.68 ± 2.95                     0.01
  Age                            --0.16 ± 0.95                     0.87
  Urinary cotinine               9.05 × 10^--4^ ± 5.42 × 10^--4^   0.10
                                                                   

###### 

Summary of multiple regression analyses of global H3K9me2 on urinary Ni levels (µg/g) with adjustment of potential confounders.

  Parameter                      Estimate ± SE                       *p*-Value
  ------------------------------ ----------------------------------- ----------------
  Without adjustment                                                 
  Intercept                      15.11 ± 1.58                        \< 1 × 10^--4^
  Urinary Ni                     --0.26 ± 0.32                       0.42
  Adjusted by age and smoking                                        
  Intercept                      24.63 ± 5.13                        \< 1 × 10^--4^
  Urinary Ni                     --0.22 ± 0.32                       0.49
  Age                            --0.20 ± 0.11                       0.07
  Smoking (self-reported)        --1.58 ± 1.48                       0.29
  Adjusted by age and cotinine                                       
  Intercept                      22.71 ± 4.67                        0.0
  Urinary Ni                     --0.22 ± 0.32                       0.50
  Age                            --0.17 ± 0.10                       0.10
  Urinary cotinine               --3.68 × 10^--5^ ± 5.88 × 10^--5^   0.53
                                                                     

For phase 2 of the study, we sought to evaluate the intraindividual variance (variance within subjects) compared with interindividual (variance between subjects) of global levels of H3K4me3, H3K9ac, and H3K9me2 in order to determine whether measurements of global levels of these histone modifications are relatively constant within subjects over time. The characteristics for participating subjects of phase 2 of the study are described in [Table 5](#t5){ref-type="table"}. As shown in [Table 6](#t6){ref-type="table"}, the variations of H3K4me3, H3K9ac, and H3K9me2 were substantially larger between subjects relative to the variations within subjects in both exposure groups, resulting in reliability coefficients (an estimate of the consistency of a set of measurements) of 0.60, 0.67, and 0.79 for H3K4me3, H3K9ac, and H3K9me2, respectively, for Ni-exposed subjects and 0.75, 0.74, and 0.97, respectively, for referent subjects. These results indicate that temporal variability within individuals is relatively small, compared with variability between subjects, suggesting that global H3K4me3, H3K9ac, and H3K9me2 histone modifications are relatively stable over time in human PBMCs from both Ni-exposed and referent subjects.

###### 

Characteristics of the Ni-exposed and referent study subjects selected to study the intra- and interindividual variations of global H3K4me3, H3K9ac, and H3K9me2.

  Parameter                                      Referent   Ni-exposed           
  ---------------------------------------------- ---------- ----------------- -- -----------------
  Age                                                       41.13 ± 8.36         41.40 ± 8.63
  Smoking (self-reported)                                                        
  Smokers \[*n* (%)\]                                       8 (53)               8 (53)
  Smoking years                                             20.88 ± 8.10         22.88 ± 6.60
  Cigarettes/day                                            18.75 ± 13.92        21.88 ± 9.23
  Urinary cotinine (µg/g creatinine)                                             
  First collection                                          325.74 ± 104.78      258.53 ± 111.63
  Second collection                                         341.92 ± 160.32      293.00 ± 148.93
  Third collection                                          356.40 ± 161.35      314.39 ± 226.22
  Urinary Ni (µg/g creatinine)                                                   
  First collection                                                               
  Mean ± SD                                                 6.86 ± 1.88          6.67 ± 3.25
  Median                                                    7.01                 5.96
  Minimum                                                   3.32                 2.19
  Maximum                                                   10.42                12.03
  10th percentile                                           4.99                 3.41
  25th percentile                                           5.49                 4.27
  75th percentile                                           8.09                 9.12
  90th percentile                                           8.77                 10.29
  Second collection                                                              
  Mean ± SD                                                 6.51 ± 2.75          10.47 ± 4.40
  Median                                                    5.73                 9.96
  Minimum                                                   3.45                 6.11
  Maximum                                                   13.47                21.97
  10th percentile                                           3.80                 6.73
  25th percentile                                           4.88                 7.10
  75th percentile                                           7.86                 11.45
  90th percentile                                           9.47                 15.02
  Third collection                                                               
  Mean ± SD                                                 9.63 ± 2.91          8.84 ± 4.58
  Median                                                    9.48                 8.02
  Minimum                                                   4.73                 5.34
  Maximum                                                   15.00                23.65
  10th percentile                                           6.69                 5.54
  25th percentile                                           7.51                 6.44
  75th percentile                                           11.11                9.40
  90th percentile                                           13.45                11.25
  Values are mean ± SD except where indicated.                                   

###### 

Intra- and interindividual variability of global H3K4me3, H3K9ac, and H3K9me2 in human PBMCs of Ni-exposed and referent study subjects.

  Parameter                                                                                              Variance between subjects   Variance within subjects   Reliability coefficient (*R*)*a*                       
  ------------------------------------------------------------------------------------------------------ --------------------------- -------------------------- ---------------------------------- ---------------- -- ------
  H3K4me3 (%)                                                                                                                                                                                                          
  Referent subjects                                                                                                                  3 × 10^--5^                                                   1 × 10^--5^         0.75
  Ni-exposed subjects                                                                                                                3 × 10^--5^                                                   2 × 10^--5^         0.60
  H3K9ac (%)                                                                                                                                                                                                           
  Referent subjects                                                                                                                  14.64                                                         5.29                0.74
  Ni-exposed subjects                                                                                                                36.69                                                         14.93               0.67
  H3K9me2 (%)                                                                                                                                                                                                          
  Referent subjects                                                                                                                  4.54 × 10^--3^                                                1.5 × 10^--4^       0.97
  Ni-exposed subjects                                                                                                                5.86 × 10^--3^                                                1.53 × 10^--3^      0.79
  Urinary Ni (µg/g creatinine)                                                                                                                                                                                         
  Referent subjects                                                                                                                  7.21                                                          5.68                0.56
  Ni-exposed subjects                                                                                                                16.53                                                         10.98               0.60
  **a**Reliability coefficient (*R*) = *variance*~between~/(*variance*~between~ + *variance*~within~).                                                                                                                 

Discussion
==========

In this first study evaluating histone modifications in relation to occupational Ni exposure in refinery workers and to human urinary Ni levels, we found highly significant elevated levels of H3K4me3 modification in Ni-exposed workers and in subjects with greater urinary Ni, consistent with previous studies reporting that exposure to Ni increases global levels of H3K4me3 *in vitro* ([@r34]). H3K9ac modifications were marginally (and not significantly) decreased in Ni-exposed subjects; however, these modifications were significantly decreased in relation to greater urinary Ni. Consistent with the negative association found between H3K9ac and urinary Ni, previous *in vitro* studies found that exposure to Ni induces histone hypoacetylation of all four core histones ([@r17]). We found lower levels of H3K9me2 in subjects with occupational exposure to Ni; however, urinary Ni was not clearly associated with modifications in this histone. These results are not consistent with a previous report that *in vitro* exposure to Ni induces an increase in global H3K9me2 ([@r7]).

Plausible mechanisms by which exposure to Ni compounds induce alterations of global levels of histone modification *in vivo* include Ni-induced inhibition of histone demethylase and acetyltransferase enzymes. In support of this, previous studies from our group examining the mechanisms by which Ni compounds alter histone modifications *in vitro* have revealed that exposure to Ni decreases histone acetylation by inhibiting histone acetyltransferase activity, but has no effect on histone deacetylases ([@r17]). We have also shown that Ni increases H3K9me2 by inhibiting the demethylating activity, by directly binding and replacing the iron(II) from the enzyme JHDM2A/JMJD1A (KDM3A), with no observable effect on methyltransferases ([@r7], [@r6], [@r8]). We also recently reported that hypoxia increases H3K4me3 by inhibition of JARID1A demethylase, and because Ni is a hypoxia mimetic, it is possible that Ni also increases H3K4me3 levels by inhibiting the JARID1A demethylase or other members of the JARID1 family ([@r35]).

It was not surprising that exposure to Ni increases histone modifications associated with gene repression decrease in H3K9ac, and also increase H3K4me3, associated with gene activation, because changes observed in previous *in vitro* studies ([@r7], [@r6]; [@r34]) also suggest that induction of both gene activating and repressive histone modifications occur as a result of exposure to specific metal compounds. Although both H3K9me2 and H3K4me3 increased after exposures to Ni, arsenic, and chromate, distinct localization of chromate-induced H3K9me2 and H3K4me3 modifications in chromatin were detected with dual immunofluorescence: H3K9me2 was primarily enriched at the periphery of the nucleus, which coincides with the location of heterochromatin, whereas H3K4me3 was exclusively enriched in the center of the nucleus (euchromatin) ([@r34]).

In a study of healthy workers at a steel plant in Brescia, Italy, [@r4] observed that global H3K4me2 was increased in association with Ni, arsenic, and iron, whereas H3K9ac was positively but not significantly associated with Ni and iron; results for H3K4me3 and H3K9me2 were not reported. The different results in our study may be explained by differences in the type of exposure of the subjects. Ni exposure in a steel plant is associated with exposures to other metals and in that case Ni exposure might track with other measured and unmeasured exposures, which may also affect levels of histone modification. Furthermore, both studies are relatively small, indicating the need for more detailed investigations in humans of metal and epigenetic modifications. Extension of studies will also need to consider whether changes in global levels of histone modifications occur in normal or malignant lung tissue exposed to Ni *in vivo*.

Our study had the advantage of investigating histone modifications in Ni-exposed subjects who worked in a Ni refinery, a setting known for excess risk of lung cancer and not notably confounded by other metal exposures. We also had the advantage of including a urinary biomarker for exposure, showing that Ni effects may occur under both occupational and environmental conditions. Because urinary Ni levels represent short-term exposure to Ni, global levels of H3K4me3 or H3K9ac histone modifications may potentially serve as biomarkers of exposure to Ni compounds. Further supporting our approach, we showed that single measurements of global H3K4me3, H3K9ac, and H3K9me2 histone modifications are representative of modification status over time.

Our study points to epigenetic control of carcinogenesis in Ni-exposed humans and points to alterations in global levels of histone modification in subjects with Ni occupational exposure comparable to limits for Ni exposures in the United States (Occupational Safety and Health Administration permissible exposure limit, 0.1 mg/m^3^ for water-soluble Ni and 1.0 mg/m^3^ for Ni subsulfide, oxide, and metallic), Canada (time-weighted average exposure values of 1.0 mg/m^3^ for Ni metal, oxides, and sulfides and 0.1 mg/m^3^ for water-soluble Ni compounds), Germany (0.5 mg/m^3^ for metallic and sulfide Ni, sulfidic ores, Ni oxide, and Ni carbonate), and the United Kingdom (maximum exposure limits of 0.5 mg/m^3^ for Ni metal and water-insoluble Ni compounds and 0.1 mg/m^3^ for water-soluble Ni). The ambient levels of environmental exposure to Ni by referent subjects are also comparable to ambient levels in the United States (120--170 ng/m^3^ in industrialized regions and large cities).

An increasing number of human diseases have been associated with aberrant epigenetic alterations, including cancer and cardiovascular, neurological, and autoimmune disorders ([@r31]). Because changes in epigenetic marks are associated with a wide range of diseases, epigenetic therapies are attractive options for risk profiling and treatment of specific disorders. Therefore, deciphering epigenetic markers in humans is crucial because the scope of epigenetic therapies is likely to expand in the coming years ([@r24]).

Conclusions
===========

Further studies should be directed toward determining whether the alterations in histone modifications induced by exposure to Ni identified in the present study are associated with risk of cancer, as well as identifying changes in gene expression and biochemical pathways affected as a result of exposure to Ni compounds. The results of this study suggest the possible use of global levels of histone modifications as biomarkers of exposure to Ni compounds. Well-characterized histone modifications may aid in the future in the diagnosis and treatment of a variety of cancers or other disease states.
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